Literature DB >> 17189147

Orbital optic nerve gliomas in children with neurofibromatosis type 1.

Janice Lasky Zeid1, Joel Charrow, Mariana Sandu, Stewart Goldman, Robert Listernick.   

Abstract

PURPOSE: To describe the clinical course and treatment of symptomatic orbital optic nerve gliomas in children with neurofibromatosis type-1 (NF-1).
METHODS: A retrospective review of the records of patients with NF-1 and symptomatic orbital optic nerve gliomas seen in a large multidisciplinary NF-1 clinic of a tertiary care children's hospital. The main outcome measures included presenting symptoms and signs, ophthalmologic examination at diagnosis, the presence of progressive disease following diagnosis, type of therapy, and the reasons therapy was instituted.
RESULTS: Twelve patients with symptomatic orbital optic nerve gliomas, all of which led to proptosis (eight girls, four boys), were identified. The mean age of diagnosis of NF-1 was 20 months; the mean age of diagnosis of the orbital optic nerve glioma was 26 months. At the time of diagnosis of the tumor, 10 of 12 patients (83%) had decreased visual acuity in the affected eye. Three patients underwent optic nerve resection; eight received chemotherapy, and one was observed without therapy. Of the eight children who received chemotherapy, progressive disease prior to treatment could be documented in only three; none of these eight children had a reproducible improvement in vision following chemotherapy. There was no demonstrable improvement in vision in any treated patient with NF-1-associated orbital optic nerve gliomas.
CONCLUSIONS: Although not definitively proven, our data and previous studies suggest that NF-1-associated orbital optic nerve gliomas should not be treated unless there is clear evidence of either ophthalmologic or radiographic progression. Surgical excision of tumors which have led to proptotic eyes without functional vision should be reserved for cosmetic purposes or to treat complications of exposed globes.

Entities:  

Mesh:

Year:  2006        PMID: 17189147     DOI: 10.1016/j.jaapos.2006.03.014

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  13 in total

1.  Orbital and nasal meningoencephaloceles secondary to chronic hydrocephalus: A rare cause of bilateral proptosis.

Authors:  Zachary B Jenner; Nuruddin Husein; Roy Riascos; Yoshua Esquenazi
Journal:  Neuroradiol J       Date:  2018-06-08

2.  Optic Nerve Gliomas.

Authors:  Edward J Wladis; Matthew A Adamo; Lauren Weintraub
Journal:  J Neurol Surg B Skull Base       Date:  2021-01-19

3.  Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients.

Authors:  Fausto J Rodriguez; Arie Perry; David H Gutmann; Brian Patrick O'Neill; Jeffrey Leonard; Sandra Bryant; Caterina Giannini
Journal:  J Neuropathol Exp Neurol       Date:  2008-03       Impact factor: 3.685

Review 4.  Optic pathway gliomas: a review.

Authors:  Iris Fried; Uri Tabori; Tarik Tihan; Arun Reginald; Eric Bouffet
Journal:  CNS Oncol       Date:  2013-03

5.  Comparison of multi-shot and single shot echo-planar diffusion tensor techniques for the optic pathway in patients with neurofibromatosis type 1.

Authors:  Chang Y Ho; Rachael Deardorff; Stephen F Kralik; John D West; Yu-Chien Wu; Chie-Schin Shih
Journal:  Neuroradiology       Date:  2019-01-25       Impact factor: 2.804

Review 6.  Optic Pathway Gliomas in Neurofibromatosis Type 1.

Authors:  Cynthia J Campen; David H Gutmann
Journal:  J Child Neurol       Date:  2018-01       Impact factor: 1.987

7.  Surgical Management of Pilocytic Astrocytoma of the Optic Nerve: A Case Report and Review of the Literature.

Authors:  Ifeoluwa Apanisile; Tamás Karosi
Journal:  Case Rep Oncol Med       Date:  2017-12-03

Review 8.  Optic Pathway Glioma in Type 1 Neurofibromatosis: Review of Its Pathogenesis, Diagnostic Assessment, and Treatment Recommendations.

Authors:  Matteo Cassina; Luisa Frizziero; Enrico Opocher; Raffaele Parrozzani; Ugo Sorrentino; Elisabetta Viscardi; Giacomo Miglionico; Edoardo Midena; Maurizio Clementi; Eva Trevisson
Journal:  Cancers (Basel)       Date:  2019-11-14       Impact factor: 6.639

9.  Advanced pharmacological therapies for neurofibromatosis type 1-related tumors.

Authors:  Thomas Foiadelli; Matteo Naso; Amelia Licari; Alessandro Orsini; Mariasole Magistrali; Chiara Trabatti; Sabino Luzzi; Mario Mosconi; Salvatore Savasta; Gian Luigi Marseglia
Journal:  Acta Biomed       Date:  2020-06-30

Review 10.  Targeted Therapies for the Neurofibromatoses.

Authors:  Lauren D Sanchez; Ashley Bui; Laura J Klesse
Journal:  Cancers (Basel)       Date:  2021-11-30       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.